This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Digna Biotech, S.L.
Drug Names(s): P-17, NAFB002
Description: NAFB002 (P17) is a synthetic peptide of 15 amino acids that inhibits TGF-beta 1.
Digna and Flamel
In June 2011, Flamel and Digna announced that the two companies entered into a joint development agreement for the pre-clinical and clinical development of P17.
In July 2013, Flamel terminated its licensing agreement with Digna related to P144.
Pink Sheet FDA Performance Tracker: CDER Approvals
Pink Sheet FDA Performance Tracker: CBER Approvals
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: